Previous close | 0.8601 |
Open | 0.8726 |
Bid | 0.8628 x 100 |
Ask | 0.9923 x 100 |
Day's range | 0.8610 - 0.8798 |
52-week range | 0.6500 - 1.4900 |
Volume | |
Avg. volume | 1,602,990 |
Market cap | 347.373M |
Beta (5Y monthly) | 2.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.08 |
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect PatientsDUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration (FDA) requesting that the Commissioner focus on and take further action to address significant off-label prescribing of fe
- Shareholders Approve Share Repurchase Program of up to $50 Million -DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This perm
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s first quarter 2024 financial results in the pre-market hours. To enhance